Direct Flow Medical, Inc. Transcatheter Aortic Valve System Demonstrates Excellent 30 Day Outcomes Following Full Enrollment of DISCOVER CE Mark Trial

Published: May 22, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PARIS--(BUSINESS WIRE)--Direct Flow MedicalĀ®, Inc., a transcatheter heart valve company focused on improving patient outcomes, today announced that it has met its primary endpoint in the fully-enrolled, 100-patient DISCOVER CE Mark Trial by achieving 99 percent freedom from all-cause mortality at 30 days. Patients were treated with the Direct Flow MedicalĀ® Transcatheter Aortic Valve System and demonstrated excellent results relative to overall patient hemodynamics, as well as the avoidance of post-procedural aortic regurgitation and adverse events. The DISCOVER Trial full 30-day outcomes were presented today by trial investigator Joachim Schofer, MD, from the Medical Care Center, Hamburg, Germany.

Help employers find you! Check out all the jobs and post your resume.

Back to news